PMP22 and Charcot-Marie-Tooth disease type 1A: Second, we delivered AAV9-miR871 through a clinically applicable method of lumbar intrathecal injection into C61-het CMT1A mice, which reproduces the clinical course, severity, and symptoms of patients with CMT1A.